161 related articles for article (PubMed ID: 11007056)
1. Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin's lymphoma.
Sasaki K; Niitsu N
Eur J Haematol; 2000 Sep; 65(3):195-202. PubMed ID: 11007056
[TBL] [Abstract][Full Text] [Related]
2. High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin's lymphoma.
Niitsu N; Iijima K
Leuk Res; 2002 Mar; 26(3):241-8. PubMed ID: 11792412
[TBL] [Abstract][Full Text] [Related]
3. A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.
Niitsu N; Iijima K; Chizuka A
Eur J Haematol; 2001 Jan; 66(1):24-30. PubMed ID: 11168504
[TBL] [Abstract][Full Text] [Related]
4. Serum levels and differential expression of CD44 in childhood leukemia and malignant lymphoma: correlation with prognostic criteria and survival.
Taçyildiz N; Cavdar AO; Yavuz G; Gözdaşoglu S; Unal E; Ertem U; Duru F; Ikinciogullari A; Babacan E; Kuzu I; Cin S
Pediatr Int; 2001 Aug; 43(4):354-60. PubMed ID: 11472578
[TBL] [Abstract][Full Text] [Related]
5. Soluble CD44 v5 and v6 in serum of patients with breast cancer. Correlation with expression of CD44 v5 and v6 variants in primary tumors and location of distant metastasis.
Lackner C; Moser R; Bauernhofer T; Wilders-Truschnig M; Samonigg H; Berghold A; Zatloukal K
Breast Cancer Res Treat; 1998 Jan; 47(1):29-40. PubMed ID: 9493973
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of some biochemical markers as prognostic factors in malignant lymphoma.
Khalifa KA; Alkilani AA; Ismail H; Soliman MA
J Egypt Natl Canc Inst; 2008 Mar; 20(1):47-54. PubMed ID: 19847281
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of soluble CD44 in patients with breast and colorectal carcinomas and non-Hodgkin's lymphoma.
Lockhart MS; Waldner C; Mongini C; Gravisaco MJ; Casanova S; Alvarez E; Hajos S
Oncol Rep; 1999; 6(5):1129-33. PubMed ID: 10425314
[TBL] [Abstract][Full Text] [Related]
8. A high serum soluble Fas/APO-1 level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.
Niitsu N; Sasaki K; Umeda M
Leukemia; 1999 Sep; 13(9):1434-40. PubMed ID: 10482996
[TBL] [Abstract][Full Text] [Related]
9. Serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant v5 (sCD44-v5), and CD44 splice variant v6 (sCD44-v6) in patients with epithelial ovarian cancer.
Gadducci A; Ferdeghini M; Fanucchi A; Annicchiarico C; Cosio S; Prontera C; Bianchi R; Genazzani AR
Anticancer Res; 1997; 17(6D):4463-6. PubMed ID: 9494551
[TBL] [Abstract][Full Text] [Related]
10. The role of alternative splicing of the adhesion molecule, CD44, in lymphoid malignancy.
Irving JA; Cain G; Howard M; Angus B; Taylor PR; Cattan AR
J Clin Pathol; 1998 Oct; 51(10):776-80. PubMed ID: 10023342
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of circulating CD44 in non-Hodgkin's lymphoma.
Ristamäki R; Joensuu H; Hagberg H; Kalkner KM; Jalkanen S
Int J Cancer; 1998 Jun; 79(3):221-5. PubMed ID: 9645341
[TBL] [Abstract][Full Text] [Related]
12. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
[TBL] [Abstract][Full Text] [Related]
13. Elevated serum levels of soluble CD44 can identify a subgroup of patients with early B-cell chronic lymphocytic leukemia who are at high risk of disease progression.
Molica S; Vitelli G; Levato D; Giannarelli D; Gandolfo GM
Cancer; 2001 Aug; 92(4):713-9. PubMed ID: 11550139
[TBL] [Abstract][Full Text] [Related]
14. [Detection of soluble interleukin-2 receptor in the serum of patients with non-Hodgkin's lymphoma].
Pérez Encinas M; Bello JL; Bendaña A; Rabuñal MJ; González S; Abuín I; Noya M; Cadarso C
Med Clin (Barc); 1998 Jul; 111(5):161-7. PubMed ID: 9732831
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.
Warzocha K; Salles G; Bienvenu J; Bastion Y; Dumontet C; Renard N; Neidhardt-Berard EM; Coiffier B
J Clin Oncol; 1997 Feb; 15(2):499-508. PubMed ID: 9053471
[TBL] [Abstract][Full Text] [Related]
16. [Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma].
Shimomura Y; Tsurumi H; Sawada M; Yamada T; Hara T; Fukuno K; Goto H; Moriwaki H
Rinsho Ketsueki; 1999 Aug; 40(8):639-45. PubMed ID: 10496038
[TBL] [Abstract][Full Text] [Related]
17. The serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant 5 (sCD44-v5), and CD44 splice variant 6 (sCD44-v6) in patients with cervical cancer.
Gadducci A; Ferdeghini M; Cosio S; Annicchiarico C; Fanucchi A; Prontera C; Bianchi R; Genazzani AR
Anticancer Res; 1998; 18(1B):537-9. PubMed ID: 9568174
[TBL] [Abstract][Full Text] [Related]
18. Elevated serum CD44 level is associated with unfavorable outcome in non-Hodgkin's lymphoma.
Ristamäki R; Joensuu H; Lappalainen K; Teerenhovi L; Jalkanen S
Blood; 1997 Nov; 90(10):4039-45. PubMed ID: 9354673
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas.
Shah N; Cabanillas F; McIntyre B; Feng L; McLaughlin P; Rodriguez MA; Romaguera J; Younes A; Hagemeister FB; Kwak L; Fayad L
Leuk Lymphoma; 2012 Jan; 53(1):50-6. PubMed ID: 21895545
[TBL] [Abstract][Full Text] [Related]
20. [Validity of the International Prognostic Index in non-Hodgkin's lymphomas of varying grades of malignancy].
Bettini R; Caronni F; Maino C; Marzetta K; Sala D; Saccà V; Gorini M
Recenti Prog Med; 2003 Nov; 94(11):494-500. PubMed ID: 14679917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
